11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The main components of metabolic syndrome (obesity, insulin resistance, hypertension and dyslipidemia) have become prevalent worldwide, and excess glucocorticoid levels have been implicated in patients with these symptoms. 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is an enzyme involved in glucocorticoid regulation through catalysis of the conversion of inactive cortisone to its active form cortisol. Numerous rodent studies have demonstrated the potential use of 11beta-HSD1 inhibitors as treatment for the components of metabolic syndrome and limited clinical data in humans have shown 11beta-HSD1 inhibition to improve glucose levels, insulin sensitivity and lipid profiles. Many organizations have been active in the 11beta-HSD1 academic and patent literature, and two previous articles from this journal have reviewed disclosures through August 2007. OBJECTIVE: To summarize the recent patent literature and progress in defining the utility of small molecule 11beta-HSD1 inhibitors. METHODS: This review covers the recent 11beta-HSD1 patent literature and clinical activity ranging from late 2007 through the end of 2008. RESULTS/CONCLUSION: The exploration of 11beta-HSD1 inhibitors continues, as a number of structural classes have been reported by several pharmaceutical companies over the past 16 months. Current clinical trials will ultimately shed light on the feasibility of 11beta-HSD1 inhibitors as pharmaceutical agents for the various components of metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“Transgenic overexpression of 11β-HSD1 in adipose tissue of mice produces intra-abdominal obesity, insulin resistance, dyslipidemia and hypertension [32-34] in the absence of elevated corticosterone, whereas mice with targeted disruption of the 11β-HSD1 gene are resistant to diet-induced obesity [35], and display impro…”
Morton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512 · cited 1×
“Transgenic overexpression of 11β-HSD1 in adipose tissue of mice produces intra-abdominal obesity, insulin resistance, dyslipidemia and hypertension [32-34] in the absence of elevated corticosterone, whereas mice with targeted disruption of the 11β-HSD1 gene are resistant to diet-induced obesity [35], and display impro…”
Cortisol secretion in relation to body fat distribution in obese premenopausal women
Mårin, P., Darin, N., Amemiya, T., Andersson, B., Jern, S., & Björntorp, P. (1992) · Metabolism · doi:10.1016/0026-0495(92)90171-6 · Cited by 458
Masuzaki, H., Yamamoto, H., Kenyon, C. J., Elmquist, J. K., Morton, N. M., Paterson, J. M., Shinyama, H., Sharp, M. G. F., Fleming, S., Mullins, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17845 · Cited by 434 · cited 1×
“Transgenic overexpression of 11β-HSD1 in adipose tissue of mice produces intra-abdominal obesity, insulin resistance, dyslipidemia and hypertension [32-34] in the absence of elevated corticosterone, whereas mice with targeted disruption of the 11β-HSD1 gene are resistant to diet-induced obesity [35], and display impro…”
Lupien, S. J., Nair, N. P. V., Briére, S., Maheu, F., Tu, M. T., Lemay, Μ., McEwen, B. S., & Meaney, M. J. (1999) · Reviews in the Neurosciences · doi:10.1515/revneuro.1999.10.2.117 · Cited by 283 · cited 1×
“Elevated glucocorticoid levels have negative effects on the neurochemistry and function of the hippocampus, and it has been proposed that exposure of the hippocampus to high levels of glucocorticoids contributes to aging-related cognitive impairment [48].”
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239 · cited 1×
“Two 11β-HSD isozymes have been identified, 11β-HSD1 and 11β-HSD2 [26,27].”
Lindsay, R. S., Wake, D. J., Nair, S., Bunt, J., Livingstone, D. E. W., Permana, P. A., Tataranni, P. A., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030017 · Cited by 225 · cited 2×
“11β-HSD1 mRNA and enzyme activity are higher in adipose tissue of obese humans [18,19,21,30] and rodents [31].”
Lavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207 · cited 1×
“In vitro biochemical characterization shows that 11β-HSD1 is an NADPHdependent bidirectional enzyme that can function as both a reductase and a dehydrogenase [12]; however, the reductase activity predominates in vivo owing to the redox potential maintained by the NADPH-generating enzyme hexose6-phosphate dehydrogenase…”
Oppermann, U. C. T., Persson, B., & Jörnvall, H. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-1-00355.x · Cited by 66 · cited 1×
“In vitro biochemical characterization shows that 11β-HSD1 is an NADPHdependent bidirectional enzyme that can function as both a reductase and a dehydrogenase [12]; however, the reductase activity predominates in vivo owing to the redox potential maintained by the NADPH-generating enzyme hexose6-phosphate dehydrogenase…”
Cited by
Coutinho, A. E., & Chapman, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.005 · Cited by 1,815
Sheng, H., & Sun, H. (2011) · Natural Product Reports · doi:10.1039/c0np00059k · Cited by 289
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Cooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
Raza, K., Hardy, R., & Cooper, M. S. (2010) · Rheumatology · doi:10.1093/rheumatology/keq212 · Cited by 31
Metadata
- Authors
- Boyle, C. D., & Kowalski, T. J.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa Healthcare
- Published
- 2009-05-21
- Volume
- 19
- Issue
- 6
- Pages
- 801-825
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2032798922
- Cited by
- 74
- References
- 9
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. https://app.cochat.ai/papers/10.1517/13543770902967658
- The paper
- Boyle, C. D., & Kowalski, T. J. (2009). 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543770902967658
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.